BioNTech (NASDAQ:BNTX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of BioNTech (NASDAQ:BNTX) in a research report report published on Thursday, Benzinga reports. HC Wainwright currently has a $113.00 price target on the stock.

Several other analysts have also recently issued reports on the stock. TD Cowen increased their price target on shares of BioNTech from $95.00 to $98.00 and gave the stock a hold rating in a research report on Tuesday, May 7th. BMO Capital Markets reduced their price target on shares of BioNTech from $123.00 to $122.00 and set an outperform rating on the stock in a research report on Tuesday, May 7th. Finally, Evercore ISI began coverage on shares of BioNTech in a research report on Tuesday, May 14th. They set an inline rating and a $100.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of Hold and a consensus price target of $111.70.

BioNTech Trading Down 2.1 %

BNTX stock traded down $1.70 during mid-day trading on Thursday, hitting $80.31. 292,376 shares of the company were exchanged, compared to its average volume of 692,018. The company has a quick ratio of 11.16, a current ratio of 11.38 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $19.09 billion, a P/E ratio of 164.02 and a beta of 0.23. The business has a fifty day simple moving average of $88.11 and a 200-day simple moving average of $90.77. BioNTech has a 12-month low of $77.81 and a 12-month high of $125.83.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, May 6th. The company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.60). The company had revenue of $203.69 million for the quarter, compared to analysts’ expectations of $589.96 million. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. On average, equities research analysts predict that BioNTech will post -2.04 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

Hedge funds have recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd increased its stake in BioNTech by 2.5% in the fourth quarter. Dynamic Technology Lab Private Ltd now owns 4,666 shares of the company’s stock valued at $492,000 after purchasing an additional 116 shares during the last quarter. Covestor Ltd grew its position in BioNTech by 47.2% in the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after buying an additional 133 shares during the last quarter. GAMMA Investing LLC grew its position in BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after buying an additional 150 shares during the last quarter. Arlington Capital Management Inc. grew its position in BioNTech by 10.0% in the 1st quarter. Arlington Capital Management Inc. now owns 2,200 shares of the company’s stock valued at $203,000 after buying an additional 200 shares during the last quarter. Finally, Midwest Professional Planners LTD. grew its position in BioNTech by 7.2% in the 1st quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company’s stock valued at $293,000 after buying an additional 212 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.